J.P. Marvel Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

J.P. Marvel Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.88M	Sell	7,810 -45	-0.6%	-$19.9K	0.45%	37
2026 Q1	$3.51M	Hold	7,855	–	–	0.5%	37
2025 Q4	$3.56M	Hold	7,855	–	–	0.49%	36
2025 Q3	$3.08M	Hold	7,855	–	–	0.45%	41
2025 Q2	$3.5M	Sell	7,855 -137	-2%	-$63.1K	0.56%	38
2025 Q1	$3.87M	Buy	7,992 +1,600	+25%	+$746K	0.67%	38
2024 Q4	$2.57M	Hold	6,392	–	–	0.42%	42
2024 Q3	$2.97M	Hold	6,392	–	–	0.49%	44
2024 Q2	$3M	Hold	6,392	–	–	0.49%	46
2024 Q1	$2.67M	Buy	6,392 +172	+3%	+$72.7K	0.46%	47
2023 Q4	$2.53M	Hold	6,220	–	–	0.5%	45
2023 Q3	$2.16M	Hold	6,220	–	–	0.47%	45
2023 Q2	$2.19M	Hold	6,220	–	–	0.46%	48
2023 Q1	$1.96M	Hold	6,220	–	–	0.44%	50
2022 Q4	$1.8M	Sell	6,220 -5	-0.1%	-$1.52K	0.42%	50
2022 Q3	$1.8M	Hold	6,225	–	–	0.46%	49
2022 Q2	$1.75M	Hold	6,225	–	–	0.42%	48
2022 Q1	$1.63M	Buy	6,225 +85	+1%	+$20.2K	0.33%	53
2021 Q4	$1.35M	Buy	+6,140	New	+$1.19M	0.26%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

J.P. Marvel Investment Advisors's VRTX Position: Q2 2026 in Review

J.P. Marvel Investment Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.57% in Q2 2026, selling an estimated $19.9K and leaving 7,810 shares worth $3.88M. The position accounts for 0.45% of the portfolio, ranked #37.

J.P. Marvel Investment Advisors first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

J.P. Marvel Investment Advisors held 7,810 shares of Vertex Pharmaceuticals worth $3.88M as of Q2 2026.
J.P. Marvel Investment Advisors sold 45 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.9K.
Vertex Pharmaceuticals made up 0.45% of J.P. Marvel Investment Advisors's portfolio in Q2 2026, its #37 holding.
J.P. Marvel Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on J.P. Marvel Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.